The widening loss is concerning, but the $76.9M cash runway supports ongoing clinical and commercial development. Traders should monitor upcoming milestones: completion of U.S. skin cancer trial recruitment (Q1 2026), pancreatic trial enrollment (Q2 2026), and initial GBM safety readout (Q2 2026). Positive data or accelerated approvals could drive upside.
Price Chart
Executive Summary
Alpha Tau Medical reported its 2025 financial results, showing a wider net loss of $42.6 million ($0.53/share) compared to $31.8 million ($0.45/share) in 2024, driven by higher R&D and G&A expenses. Despite the increased loss, the company highlighted significant clinical and regulatory progress, including Japanese marketing approval for head and neck cancer, five U.S. trial approvals, and positive pancreatic cancer data presented at ASCO GI, while ending the year with $76.9 million in cash.
Key Financial Metrics
Key Facts
- Net loss widened to $42.6M in 2025 from $31.8M in 2024
- R&D expenses increased to $32.1M from $27.0M in 2024
- Cash, cash equivalents, and deposits totaled $76.9M as of Dec 31, 2025
- Received marketing approval in Japan for head and neck cancer
- Five U.S. clinical trials approved in parallel, including for prostate and brain cancers
- Positive pancreatic cancer data: 22% ORR and 81% DCR in 32-patient study
- First patient treated in U.S. recurrent glioblastoma trial
- Submitted first module of PMA application to FDA for skin cancer
Financial Impact
Net loss increased by 34% YoY to $42.6 million; cash position grew by $14 million to $76.9 million
Risk Factors
- Continued losses and need for future funding could lead to dilution
- Clinical trial delays or adverse results could impair development timelines
- Regulatory setbacks in U.S. or other markets despite Japanese approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252290 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 6-K | $14.11 $15.19 | ▲ +7.65% | ▲ +7.84% | $14.77 (+4.68%) |
Aug 10, 2026 7w ago | 6-K | $14.27 $14.27 | · 0.00% | ▲ +1.06% | $14.77 (+3.50%) |
Aug 10, 2026 7w ago | Press Release | $14.27 $14.27 | · 0.00% | ▲ +1.06% | $14.77 (+3.50%) |
Aug 10, 2026 7w ago | 6-K | $13.60 $14.84 | ▲ +9.12% | ▲ +10.03% | $14.77 (+8.60%) |
Jul 21, 2026 10w ago | 6-K | $13.32 $14.26 | ▲ +7.06% | ▲ +4.50% | $14.77 (+10.89%) |
Jul 15, 2026 11w ago | 6-K | $12.46 $13.87 | ▲ +11.32% | ▲ +8.97% | $14.77 (+18.54%) |
Jun 23, 2026 14w ago | 6-K | $10.05 $13.01 | ▲ +29.45% | ▲ +27.52% | $14.77 (+46.97%) |
Jun 3, 2026 17w ago | Press Release | $10.58 $13.23 | ▲ +25.05% | ▲ +26.05% | $14.77 (+39.60%) |
May 11, 2026 20w ago | Press Release | $10.34 $9.19 | ▼ −11.12% | ▼ −10.82% | $14.77 (+42.84%) |
May 8, 2026 21w ago | Press Release | $8.51 $9.35 | ▲ +9.87% | ▲ +9.85% | $14.77 (+73.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access